Please login to the form below
Epidarex
This page shows the latest Epidarex news and features for those working in and with pharma, biotech and healthcare.
Novartis invests $1.3bn in protein degradation technology
Dunad, which was only founded last year, is backed by founding investor Epidarex Capital as well as BioGeneration Ventures.
Latest news
-
Daily Brief: Charity criticises NHSE and Vertex over Orkambi access, Sema scores again, NodThera launched
The fundraising was co-led by leading healthcare investors Sofinnova Partners and 5AM Ventures, with Epidarex Capital and F-Prime Capital Partners also taking part.
-
Lilly invests in UK life sciences via biotech fund
The fund will also tap into Epidarex' links with Scottish universities - including Edinburgh, Glasgow and Aberdeen - and try to encourage the creation of spin-out companies, said the investors. ... The completion of our fund is a significant validation
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
IGEM Therapeutics appoints Dr Tim Wilson as CEO
has raised £2m from Epidarex Capital, in order to progress its pipeline of IgE antibody drug candidates. ... Dr Peter Finan, venture partner and Epidarex Capital, said: “We are very pleased to have been able to recruit Dr Tim Wilson to lead IGEM as CEO
-
Caldan Therapeutics appoints CEO
Dr Liz Roper, partner at Epidarex Capital, which backs Caldan Therapeutics, said: “We are delighted to welcome Mark on board to lead Caldan Therapeutics moving forward.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Pfizer, Mylan move ahead with generics merger and spin-out
PMHub
foxandcat.online
We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
